Literature DB >> 1321420

Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022.

U Kohnert1, R Rudolph, J H Verheijen, E J Weening-Verhoeff, A Stern, U Opitz, U Martin, H Lill, H Prinz, M Lechner.   

Abstract

BM 06.022 is a t-PA deletion variant which comprises the kringle 2 and the protease domain. Production of BM 06.022 in Escherichia coli leads to the formation of inactive inclusion bodies, which have to be refolded by an in vitro refolding process to achieve activity and proper structure of the domains. We analysed the biochemical properties of BM 06.022 to obtain some information about the structure of kringle 2 and the protease as compared with the structure of these domains in the intact t-PA molecule. The kinetic analysis of the amidolytic activity of BM 06.022 and CHO-t-PA yielded similar values for kcat (13.9 s-1 and 11.4 s-1 for the single chain forms and 33.9 s-1 and 27.1 s-1 for the two chain forms of BM 06.022 and CHO-t-PA, respectively) and for Km (2.5 mM and 2.1 mM for the single chains forms and 0.5 mM and 0.3 mM for the two chain forms of BM 06.022 and CHO-t-PA, respectively). BM 06.022 and CHO-t-PA have the same plasminogenolytic activity in the absence of CNBr fragments of fibrinogen. However, BM 06.022 has a lower plasminogenolytic activity in the presence of CNBr fragments of fibrinogen and a lower affinity to fibrin as compared with CHO-t-PA. The affinity of BM 06.022 for fibrin is completely suppressed by 0.3 mM epsilon-aminocaproic acid, while the intact t-PA has a residual affinity of approximately 30%. The dissociation constants for the interaction with the lysine analogue epsilon-aminocaproic acid are 0.10 mM and 0.09 mM for BM 06.022 and the intact t-PA, respectively. Furthermore, BM 06.022 and CHO-t-PA are inhibited by PAI-1 in a similar manner.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321420     DOI: 10.1093/protein/5.1.93

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  21 in total

Review 1.  Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective.

Authors:  U Martin; B Kaufmann; G Neugebauer
Journal:  Clin Pharmacokinet       Date:  1999-04       Impact factor: 6.447

2.  The evolution of recombinant thrombolytics: Current status and future directions.

Authors:  Yogender Pal Khasa
Journal:  Bioengineered       Date:  2016-10-03       Impact factor: 3.269

3.  Expression of the truncated tissue plasminogen activator (K2S) gene in tobacco chloroplast.

Authors:  Maryam Abdoli-Nasab; Mokhtar Jalali-Javaran; Rosa M Cusidó; Javier Palazón; Amin Baghizadeh; Houshang Alizadeh
Journal:  Mol Biol Rep       Date:  2013-10-11       Impact factor: 2.316

Review 4.  Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction.

Authors:  S Noble; D McTavish
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

5.  Cosecretion of chaperones and low-molecular-size medium additives increases the yield of recombinant disulfide-bridged proteins.

Authors:  J Schäffner; J Winter; R Rudolph; E Schwarz
Journal:  Appl Environ Microbiol       Date:  2001-09       Impact factor: 4.792

6.  Expression of active recombinant human tissue-type plasminogen activator by using in vivo polyhydroxybutyrate granule display.

Authors:  Yanping Geng; Shengjun Wang; Qingsheng Qi
Journal:  Appl Environ Microbiol       Date:  2010-09-10       Impact factor: 4.792

7.  Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.

Authors:  Sergei Zaitsev; Sergei Zaitzev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Khalil Bdeir; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2009-12-01       Impact factor: 4.030

8.  Expression of a novel chimeric truncated t-PA in CHO cells based on in silico experiments.

Authors:  Fatemeh Davami; Soroush Sardari; Keivan Majidzadeh-A; Mehdi Hemayatkar; Farzaneh Barkhrdari; Maryam Omidi; Mehrnaz Azami; Ahmad Adeli; Noushin Davoudi; Fereidoun Mahboudi
Journal:  J Biomed Biotechnol       Date:  2010-09-22

9.  Expression of active human tissue-type plasminogen activator in Escherichia coli.

Authors:  J Qiu; J R Swartz; G Georgiou
Journal:  Appl Environ Microbiol       Date:  1998-12       Impact factor: 4.792

10.  Mapping of the catalytic site of CHO-t-PA and the t-PA variant BM 06.022 by synthetic inhibitors and substrates.

Authors:  J Stürzebecher; U Neumann; U Kohnert; G B Kresse; S Fischer
Journal:  Protein Sci       Date:  1992-08       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.